REGN · Regeneron Pharmaceuticals, Inc.
$803.48
-2.49 (-0.31%)
At close · Aug 14
Market Cap
$82.72B
Shares
102.95M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-30 | — | |
| 10-Q | 2026-07-30 | 2026-06-30 | |
| 8-K | 2026-07-06 | — | |
| 8-K | 2026-06-17 | 2026-06-12 | |
| Investor Event Transcript | 2026-06-08 | 2026-06-30 | |
| 10-Q | 2026-04-29 | 2026-03-31 | |
| 8-K | 2026-04-29 | — | |
| DEF 14A | 2026-04-24 | 2026-06-12 | |
| 8-K | 2026-04-08 | — | |
| 10-K | 2026-02-04 | 2025-12-31 | |
| 8-K | 2026-01-30 | — | |
| 8-K | 2026-01-12 | — | |
| 10-Q | 2025-10-28 | 2025-09-30 | |
| 8-K | 2025-10-28 | — | |
| 8-K | 2025-10-06 | — | |
| 10-Q | 2025-08-01 | 2025-06-30 | |
| 8-K | 2025-08-01 | — | |
| 8-K | 2025-06-18 | 2025-06-13 | |
| 8-K | 2025-04-29 | — | |
| DEF 14A | 2025-04-29 | 2025-06-13 | |
| 10-Q | 2025-04-29 | 2025-03-31 | |
| 10-K | 2025-02-05 | 2024-12-31 | |
| 8-K | 2025-02-04 | — | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-10-31 | — | |
| 10-Q | 2024-10-31 | 2024-09-30 | |
| 8-K | 2024-10-07 | — | |
| 8-K | 2024-08-01 | — | |
| 10-Q | 2024-08-01 | 2024-06-30 | |
| 8-K | 2024-07-08 | — | |
| 8-K | 2024-06-20 | 2024-06-14 | |
| 8-K | 2024-05-02 | — | |
| 10-Q | 2024-05-02 | 2024-03-31 | |
| DEF 14A | 2024-04-25 | 2024-06-14 | |
| 10-K | 2024-02-05 | 2023-12-31 | |
| 8-K | 2024-02-02 | — | |
| 8-K | 2024-01-31 | 2024-01-26 | |
| 8-K | 2024-01-08 | — | |
| 8-K | 2023-11-02 | — | |
| 10-Q | 2023-11-02 | 2023-09-30 | |
| 8-K | 2023-10-05 | — | |
| 8-K/A | 2023-09-08 | 2023-06-09 | |
| 8-K | 2023-09-08 | 2023-09-01 | |
| 8-K | 2023-08-03 | — | |
| 10-Q | 2023-08-03 | 2023-06-30 | |
| 8-K | 2023-06-14 | 2023-06-09 | |
| 10-Q | 2023-05-04 | 2023-03-31 | |
| 8-K | 2023-05-04 | — | |
| DEF 14A | 2023-04-21 | 0001-01-01 | |
| 8-K | 2023-04-17 | 2023-04-14 |
Showing 1–50 of 100 filings
Key facts
CIK
872589
CUSIP
75886F107
13F (30d)
1194 filings
1154 filers
Visit website
Investor relations